tamsulosin has been researched along with Disease Exacerbation in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Averbeck, MA; Concas, F; Cortés, V; Gravas, S; Kamola, PJ; Kattan, MW; Lulic, Z; Manyak, M; Oelke, M; Palacios-Moreno, JM; Roehrborn, CG; Thompson, D | 1 |
| Chavan, C; D'Agate, S; Della Pasqua, O; Manyak, M; Michel, MC; Oelke, M; Palacios-Moreno, JM; Roehrborn, CG | 1 |
| Brotherton, B; Calomfirescu, N; Manyak, MJ; Oyarzabal Perez, I; Palacios, JM; Roehrborn, CG; Roos, EP; Vasylyev, A | 1 |
| Bassi, PF; Brescia, A; Gardi, M; Pinto, F; Racioppi, M; Sacco, E; Totaro, A; Volpe, A | 1 |
| Barkin, J; Damião, R; Gagnier, RP; Major-Walker, K; Montorsi, F; Morrill, BB; Nandy, I; Roehrborn, CG; Siami, P | 1 |
| Chantada, V; Fraga, A; Gagnier, P; Haillot, O; Höfner, K; Maciukiewicz, P; Morrill, B; Pushkar, D; Tammela, T | 1 |
| Horita, H; Masumori, N; Miyao, N; Sato, E; Sunaoshi, K; Takeyama, K; Tanaka, Y; Tsukamoto, T | 1 |
| Doyle, S; Hunjan, M; Posnett, J; Walker, A | 1 |
1 review(s) available for tamsulosin and Disease Exacerbation
| Article | Year |
|---|---|
Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Age Factors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Azasteroids; Biomarkers, Tumor; Disease Progression; Dutasteride; Enzyme Inhibitors; Evidence-Based Medicine; Humans; Male; Practice Guidelines as Topic; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Risk Factors; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention | 2009 |
3 trial(s) available for tamsulosin and Disease Exacerbation
| Article | Year |
|---|---|
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Azasteroids; Brazil; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; North America; Proportional Hazards Models; Prostatic Hyperplasia; Risk Assessment; Risk Factors; Severity of Illness Index; Sulfonamides; Tamsulosin; Time Factors; Treatment Outcome; Urinary Retention; Urologic Surgical Procedures, Male | 2010 |
The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Azasteroids; Disease Progression; Drug Therapy, Combination; Dutasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention | 2011 |
α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Disease Progression; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Dropouts; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention; Urination Disorders | 2013 |
4 other study(ies) available for tamsulosin and Disease Exacerbation
| Article | Year |
|---|---|
Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
Topics: Azasteroids; Disease Progression; Drug Therapy, Combination; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention | 2023 |
Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
Topics: 5-alpha Reductase Inhibitors; Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Disease Progression; Drug Combinations; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Risk Assessment; Severity of Illness Index; Symptom Assessment; Tamsulosin; Time Factors; Urinary Retention | 2021 |
Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Disease Progression; Drug Therapy, Combination; Dutasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Watchful Waiting | 2017 |
Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Dutasteride; Humans; Male; Markov Chains; Middle Aged; Practice Guidelines as Topic; Prostatic Hyperplasia; Quality-Adjusted Life Years; State Medicine; Sulfonamides; Tamsulosin; Treatment Outcome; United Kingdom | 2013 |